Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 777-786

  Reid, Joel M ^a   Buhrow, Sarah A ^a   Kuffel, Mary J ^a   Jia, Lee ^b   Spanswick, Victoria J ^c   Hartley, John A ^c   Thurston, David E ^d   Tomaszewski, Joseph E ^b   Ames, Matthew M ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Comet assay; DNA damage; Metabolism; Pharmacodynamics; Pharmacokinetics; Pyrrolobenzodiazepine dimer

Indexed keywords

ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CELL DNA; CYTOCHROME P450 3A; CYTOCHROME P450 3A11; CYTOCHROME P450 3A2; DIMER; DRUG METABOLITE; NSC 694501; SG 2000; SJG 136; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMET ASSAY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DNA CROSS LINKING; DNA DAMAGE; DNA STRAND BREAKAGE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; IN VIVO STUDY; LIVER MICROSOME METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZODIAZEPINONES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMET ASSAY; DNA; DNA DAMAGE; HALF-LIFE; INDICATORS AND REAGENTS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MONOCYTES; PHARMACEUTICAL SOLUTIONS; PYRROLES; RATS; RATS, INBRED F344;

EID: 79955801932     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1517-4     Document Type: Article

References (25)

1. ′-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity J Chem Soc Chem Commun 9 797 798
2. ′ ether-linked C2-exo-unsaturated pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD) dimers J Med Chem 47 5 1161 1174 14971896 10.1021/jm030897l 1:CAS:528: DC%2BD2cXnvFWhsQ%3D%3D
3. Thurston DE (1993) Advances in the study of pyrrolo[2, 1-c][1,4]benzodiazepine (PBD) antitumor antibiotics. In: Neidle S, Waring MJ (ed) Topics in molecular and structural biology: molecular aspects of anticancer drug-DNA interactions. The MacMillan Press Ltd., London, pp 54-88
4. DS Bose AS Thompson J Ching 1992 Rational design of a highly efficient irreversible DNA interstrand coss-linking agent based on the pyrrolobenzodiazepine ring system J Am Chem Soc 114 4939 4941 10.1021/ja00038a089 1:CAS:528:DyaK38XisFGmurs%3D
5. M Smellie LR Kelland DE Thurston RL Souhami JA Hartley 1994 Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents Br J Cancer 70 1 48 53 8018540 10.1038/bjc.1994.248 1:CAS:528:DyaK2cXmslWnsLg%3D
6. MI Walton P Goddard LR Kelland DE Thurston KR Harrap 1996 Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120 Cancer Chemother Pharmacol 38 5 431 438 8765436 10.1007/s002800050507 1:CAS:528:DyaK28XlsFSqu7w%3D
7. MC Alley MG Hollingshead CM Pacula-Cox WR Waud JA Hartley PW Howard SJ Gregson DE Thurston EA Sausville 2004 SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations Cancer Res 64 18 6700 6706 15374987 10.1158/0008-5472.CAN-03-2942 1:CAS:528:DC%2BD2cXnsFOksr0%3D
8. JA Hartley VJ Spanswick N Brooks PH Clingen PJ McHugh D Hochhauser RB Pedley LR Kelland MC Alley R Schultz MG Hollingshead KM Schweikart JE Tomaszewski EA Sausville SJ Gregson PW Howard DE Thurston 2004 SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity Cancer Res 64 18 6693 6699 15374986 10.1158/0008-5472.CAN-03-2941 1:CAS:528:DC%2BD2cXnsFOksrw%3D
9. CJ Pepper RM Hambly CD Fegan P Delavault DE Thurston 2004 The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill Cancer Res 64 18 6750 6755 15374993 10.1158/0008-5472.CAN-04-1713 1:CAS:528:DC%2BD2cXnsFOks7g%3D
10. M Smellie DS Bose AS Thompson TC Jenkins JA Hartley DE Thurston 2003 Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers Biochem 42 27 8232 8239 10.1021/bi034313t 1:CAS:528:DC%2BD3sXksF2kt78%3D
11. KM Rahman AS Thompson CH James M Narayanaswamy DE Thurston 2009 The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links J Am Chem Soc 131 38 13756 13766 19725510 10.1021/ja902986x 1:CAS:528: DC%2BD1MXhtV2mur3I
12. D Hochhauser T Meyer VJ Spanswick J Wu PH Clingen P Loadman M Cobb L Gumbrell RH Begent JA Hartley D Jodrell 2009 Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors Clin Cancer Res 15 6 2140 2147 19276288 10.1158/1078-0432.CCR-08-1315 1:CAS:528:DC%2BD1MXjtF2rurg%3D
13. Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Wade Calcutt M, Rizvi NA (2010) A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 65(5):833-838
14. Puzanov I, Lee W, Berlin JD, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Hartley JA, Chen AP, Rothenburg ML (2008) Final results of phase I and pharmacokinetic trial of SJG136 administered on a daily x 3 schedule. J Clin Oncol 26 (suppl):2504
15. GP Wilkinson JP Taylor S Shnyder P Cooper PW Howard DE Thurston TC Jenkins PM Loadman 2004 Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent Invest New Drugs 22 3 231 240 15122070 10.1023/B:DRUG.0000026249.97007.60 1:CAS:528:DC%2BD2cXjsF2is78%3D
16. Spanswick VJ, Hartley JM, Ward TH, Hartley JA (1999) Measurement of drug-indcued DNA interstrand crosslinking using the single cell gel electrophoresis (Comet) assay. In: Brown B (ed) Cytotoxic drug resistance mechanisms, methods in molecular medcine. Humana Press, USA, pp 143-154
17. PL Olive JP Banath RE Durand 1990 Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay Radiat Res 122 1 86 94 2320728 10.2307/3577587 1:CAS:528: DyaK3cXhslCrtLw%3D
18. C Helma M Uhl 2000 A public domain image-analysis program for the single-cell gel-electrophoresis (comet) assay Mutat Res 466 1 9 15 10751720 1:CAS:528:DC%2BD3cXitFKqtbw%3D
19. SA Buhrow JM Reid L Jia RM McGovern JM Covey DJ Kobs IM Grossi MM Ames 2006 LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501) J Chromatogr B Analyt Technol Biomed Life Sci 840 1 56 62 16730244 10.1016/j.jchromb.2006.04.031 1:CAS:528: DC%2BD28Xns12ms7Y%3D
20. FP Guengerich 1999 Cytochrome P-450 3A4: regulation and role in drug metabolism Annu Rev Pharmacol Toxicol 39 1 17 10331074 10.1146/annurev.pharmtox. 39.1.1 1:CAS:528:DyaK1MXjtVejtrc%3D
21. P Soucek I Gut 1992 Cytochromes P-450 in rats: structures, functions, properties and relevant human forms Xenobiotica 22 1 83 103 1615711 10.3109/00498259209053106 1:CAS:528:DyaK38XhtVeju7g%3D
22. JM Hartley VJ Spanswick M Gander G Giacomini J Whelan RL Souhami JA Hartley 1999 Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay Clin Cancer Res 5 3 507 512 10100700 1:STN:280:DyaK1M7pvVOquw%3D%3D
23. VJ Spanswick C Craddock M Sekhar P Mahendra P Shankaranarayana RG Hughes D Hochhauser JA Hartley 2002 Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma Blood 100 1 224 229 12070031 10.1182/blood.V100.1.224 1:CAS:528:DC%2BD38XltF2rsbY%3D
24. SD Webley RJ Francis RB Pedley SK Sharma RH Begent JA Hartley D Hochhauser 2001 Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material Br J Cancer 84 12 1671 1676 11401322 10.1054/bjoc.2001.1843 1:CAS:528:DC%2BD3MXlt1OhtL0%3D
25. RL Petrusek EL Uhlenhopp N Duteau LH Hurley 1982 Reaction of anthramycin with DNA. Biological consequences of DNA damage in normal and xeroderma pigmentosum cell J Biol Chem 257 11 6207 6216 7076670 1:CAS:528: DyaL38Xktleiu7o%3D